ArticleProceedings (Baylor University. Medical Center)2026
Rectifying referrals: genetics testing is underutilized in rectal cancer patient care.
Article in Proceedings (Baylor University. Medical Center), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The National Comprehensive Cancer Network recommends microsatellite instability (MSI)/mismatch repair (MMR) testing to guide genetic counseling referrals for Lynch syndrome (LS) in patients with colorectal cancer. Studies show poor adherence with genetic counseling referral guidelines. Colon and rectal cancers are frequently treated as one entity despite molecular, epidemiologic, and biologic differences. Methods: We investigated facility- and patient-level adherence with genetics testing/referral guidelines for LS and other germline mutations among rectal cancer patients at one institution. This is a retrospective review of patients with rectal cancer at a tertiary hospital from 2018 to 2023, excluding years 2020 to 2022 to minimize confounding factors associated with COVID-19. Indications for genetic testing/referrals were based on the Collaborative Group of the Americas on Inherited Colorectal Cancer guidelines. Results: We sampled 177 patients, aged 27 to 96 years. A total of 149 (84.2%) underwent MMR/MSI testing; 47 (26.6%) were eligible for genetics referral. Nineteen (40.4%) were referred to genetics, and 14 (73.7%) underwent counseling/testing. One patient was diagnosed with LS, two with MUTYH-associated polyposis, and one with BRCA2. Conclusion: This study demonstrates poor facility-level adherence with MSI/MMR testing recommendations and poor patient-level compliance with genetic referrals in rectal cancer. When recommendations were met, patients with germline mutations benefited from adjustments to their disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.